Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of “Buy” by Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOKGet Rating) have earned a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $47.20.

STOK has been the topic of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Friday, April 1st. Bank of America decreased their price objective on Stoke Therapeutics from $43.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday, March 16th. Jefferies Financial Group initiated coverage on Stoke Therapeutics in a research report on Monday, January 31st. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Zacks Investment Research downgraded Stoke Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, March 16th.

Hedge funds and other institutional investors have recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Stoke Therapeutics in the third quarter worth approximately $130,000. Virtus ETF Advisers LLC grew its stake in Stoke Therapeutics by 64.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 9,070 shares of the company’s stock worth $218,000 after purchasing an additional 3,568 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in Stoke Therapeutics by 9.9% in the first quarter. DekaBank Deutsche Girozentrale now owns 10,000 shares of the company’s stock worth $222,000 after purchasing an additional 900 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Stoke Therapeutics in the fourth quarter worth approximately $225,000. Finally, Invesco Ltd. grew its stake in Stoke Therapeutics by 16.5% in the third quarter. Invesco Ltd. now owns 9,325 shares of the company’s stock worth $237,000 after purchasing an additional 1,323 shares in the last quarter. Hedge funds and other institutional investors own 99.87% of the company’s stock.

Shares of NASDAQ:STOK traded up $1.17 during mid-day trading on Friday, reaching $14.89. The stock had a trading volume of 375,041 shares, compared to its average volume of 243,121. The company has a market cap of $582.79 million, a P/E ratio of -5.89 and a beta of 0.65. Stoke Therapeutics has a 1 year low of $12.59 and a 1 year high of $41.60. The business’s 50 day moving average price is $19.69 and its 200 day moving average price is $20.91.

Stoke Therapeutics (NASDAQ:STOKGet Rating) last posted its earnings results on Tuesday, May 10th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($1.02). As a group, equities research analysts anticipate that Stoke Therapeutics will post -2.4 EPS for the current year.

Stoke Therapeutics Company Profile (Get Rating)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.

Read More

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.